Ardelyx's tenapanor, or RDX5791, met the primary and secondary endpoints in a late-stage study measuring its ability to treat irritable bowel syndrome with constipation versus a placebo after failing to meet one of its secondary endpoints in an earlier Phase III trial in the spring. The company plans to file a new-drug application with the FDA in the second half of next year.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.